Inpatient venous thromboembolism (VTE) is a priority preventable illness; risk in cancer varies and prophylaxis is inconsistently used. A previously validated tool (Khorana Score, [KS]) identifies VTE risk in cancer outpatients with 5 easily available variables but has not been studied in the inpatient setting. We evaluated the validity of KS in predicting VTE risk in hospitalized cancer patients. We (OR 0.57,. Recursive partitioning analysis suggested optimal cut point for KS is 2 (OR 1.82, 1.23-2.69). This is the first report validating KS as a risk tool to predict VTE in hospitalized cancer patients. Using this tool could lead to more consistent and successful application of inpatient thromboprophylaxis.
| I N T R O D U C T I O N
The incidence of venous thromboembolism (VTE) in hospitalized cancer patients has been shown to be considerably higher than the incidence (<1%) reported in acutely ill medical patients without cancer. [1] [2] [3] The occurrence of VTE in cancer patients has several adverse consequences including increased risk of inpatient mortality, VTE recurrence, requirement for long-term therapeutic anticoagulation with a high risk of major bleeding, negative impact on quality of life and increased consumption of health care resources. [4] [5] [6] [7] [8] Thromboprophylaxis in hospitalized cancer patients is almost universally recommended, 3, 9 and quality panels and regulators have focused on inpatient VTE as a priority preventable illness; VTE prophylaxis has even been introduced as an important pay-for-performance measure. 10, 11 However, despite the known increased risk; prophylaxis rates amongst hospitalized cancer patients are inconsistent and not risk-adjusted. [12] [13] [14] A risk assessment tool could optimize benefit to patients and provide clinicians with a formalized method to determine need for prophylaxis and has been strongly advocated for by the American Society Of Clinical Oncology and the American Society of Chest Physicians. 15, 16 Indeed a recent commentary cited the current lack of evidence to guide best practice for prophylaxis of inpatient VTE in malignancy "unacceptable". 17 Multiple scoring systems to predict inpatient VTE currently exist; two in particular are widely cited -the Padua Prediction Score 18 and IMPROVE VTE risk assessment tool; 19, 20 Unfortunately, both have been derived from populations of medically ill hospitalized patients and neither have been validated specifically for hospitalized cancer patients.
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A risk assessment model generally known as the Khorana Score (KS) to predict VTE in ambulatory cancer patients has been developed 21 and subsequently externally validated in multiple cohort studies. [22] [23] [24] It was developed from a prospective registry, using a Yes  264  9  41  16  No  2516  91  65  3   Surgery during hospitalization  Yes  89  33  15  17  No  2691  97  91  3   Length of stay  0-8  1821  66  14  0  9-17  508  18  14  6  18-29  292  10  29  10  30  159  25  30  19 Khorana score Low Risk (0)  707  25  18  3  Intermediate Risk (1-2)  1710  62  68  4  High Risk (3)  363  13  20  6  0  707  25  18  3  1  1031  37  35  3  2  679  24  33  5  3  278  10  14  5  4  7 7  3  5  7  5  8  <1  1  1 3  0-1  1738  63  53  3  2-5  1042  37  53  5   Model score for platelet count  0  2456  88  90  4  1  326 Baseline data collected included patient demographics, BMI, cancer type, use of anticoagulants and antiplatelet agents on admission, laboratory values (up to 48 h from admission) and primary indication for admission. However data on dosage of anticoagulation (ie, therapeutic or prophylactic) was not available.
Admission indications were grouped into 9 categories. Data were also collected on length of stay (LOS) and transfer to ICU or surgery during hospitalization.
Standard descriptive statistics were used to describe characteristics of study patients. For each characteristic, the number and percentage of patients with VTE was described. Recursive partitioning analysis (RPA) was used to identify a cut point in KS that best predicted VTE risk. Three variations of KS were used in the analysis: the published and validated risk score (0 low, 1-2 intermediate, and 3 high), the actual score (range 0-5 in this study), and the RPA risk cut point (0-1 low, 2 high). Logistic regression analysis was used to identify risk factors for VTE, with results summarized as odds ratio (OR) and 95%
confidence interval (CI). A stepwise selection procedure with a variable entry criterion of P .10 and a variable retention criterion of P .05
was used to identify a multivariable model; this model was confirmed with bootstrap analysis. In brief, 1000 samples of size 2780 were randomly selected with replacement from the study data and stepwise logistic regression analysis was performed on these samples. Variables that occurred in >50% of these models were considered to be significant. Model-based probabilities of VTE were calculated for combinations of significant multivariable risk factors. All statistical tests were twosided; P .05 indicated statistical significance. Data were analyzed using SAS software, Version 9.4 (SAS Institute, Cary, North Carolina, USA).
| R E S U L T S 3.1 | Study population
The study population comprised 2780 patients (Table 1) . Of these, 1545 (56%) were male, and median age was 62 (range, 19-98) years. A total of 1728 (62%) had solid tumors and 1052 (38%) patients had a hematologic malignancy. The most common primary sites for solid tumors included gastrointestinal tract (n 5 556; 20%, including 6% colorectal cancer), lung (n 5 361; 13%), breast (n 5 167; 6%) and head and neck (n 5 139; 5%). The most common sites for hematologic malignancies included leukemia and lymphoma (14% each) and myeloma (8%). Reasons for admission were grouped into nine categories of which elective chemotherapy (571, 21%), infection (552, 20%) and gastrointestinal symptoms (386, 14%) were the most frequent. Median LOS was five days with a range of 0-152 days (Patients in observation for less than two nights, would be classified as 0 admission days). Use of anticoagulation and antiplatelet medications occurred on day of admission in 65% (n 5 1800) and 14% (n 5 379) of patients respectively and increased to 77% (n 5 2140) and 18% (n 5 500) when including use anytime during admission. During hospitalization, 9% (n 5 264) of patients were transferred to the intensive care unit and 3% (n 5 89) had surgery. In-hospital mortality was 5% (n 5 138).
| VTE events
VTE occurred in 106 patients (3.8%). Median time to first VTE was 10 days (range 1-137). All VTE events were vetted by manual screening of records. Patients that had VTE events soon after admission (eg, 1-2 days), had either recent negative studies prior to admission and had no 48 of 106 VTE patients had an admission prior to the study admission. In these 48, LOS of the prior admission was a median of 5 days (range 1-44). The prior admission began at a median of 74 days, (range 8-1042) before the study admission.
| Univariate analysis
Variables significantly associated with inpatient VTE on univariate analysis (Table 2) 
| Model-based probability
Model-based probability of VTE was calculated for combinations of variables from the multivariable model (Table 4) . Age is a continuous variable so for the purpose of this analysis, age cut-points of 25, 50, and 75 were selected to represent a reasonable age spectrum within the range of the data. The probability of VTE ranged from 1.2% in patients with lowest risk profile (low-risk KS, female, older and received anticoagulation) to 15.6% in those with the highest risk profile (highrisk KS, male, younger and not receiving anticoagulation).
| DISCUSSION
We conducted a validation study of a risk assessment model previously utilized for ambulatory cancer outpatients in a cohort of hospitalized cancer patients. We found that this risk tool is significantly associated with the risk of inpatient VTE. This represents the first validation of a risk assessment tool specifically for hospitalized cancer patients.
The 3.8% rate of inpatient VTE reported by us is consistent with the rate of 4.1% a large study of 1 824 316 hospitalizations at 133 U.S medical centers that utilized the University Health System Consortium. It also falls within the range described in prior data of 0.6%-8%. 2, 8, [25] [26] [27] This range is at least in part attributable to heterogeneity of study populations across studies, with a variable distribution of the several risk factors that have been associated with cancer-related thrombosis. 28, 29 We note here that a significant proportion (65%) of patients received anticoagulants on admission, which have been clearly shown to reduce the risk of hospital-acquired VTE and rates would likely have been higher without use of prophylaxis.
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In our study, a higher KS was significantly associated with the risk for VTE despite increased use of anticoagulants in this population. The incidence of VTE in the high-risk group (KS 3) was associated with a VTE incidence of 7% over a median of 6 months in the original study 21 and 17% in the external validating Vienna cohort, 23 which utilized a significantly longer follow-up. In our study with a median LOS of 5 days, the incidence of inpatient VTE in patients with high-risk KS was 5.5%
whereas patients with low-risk KS had incidence of 2.5%; the inherent differences in the acuity of patients hospitalized as compared to their counterparts in the clinic makes direct comparisons challenging. In addition, a high proportion of patients received thromboprophylaxis in this study (as recommended by most guidelines) whereas outpatient thromboprophylaxis is not routinely employed. Importantly, in multivariable analysis, our data suggests that high-risk KS was associated with a 2.5-fold increase in the risk of developing VTE when compared to patients with low-risk KS.
Via RPA, the optimal cut off for KS was 2, which remained significant in multivariable analysis. Other studies have also suggested that this cut-off of risk score is optimal to differentiate risk. Ay et al., 23 utilizing a prospective cohort of cancer patients with newly diagnosed cancer or progression of disease after complete or partial remission,
showed that a KS of 2 was associated with a HR of 5.5 (95% CI 2.4-12.6). In a recent prospective study, rate of VTE was 11% in patients with KS > 2 further supporting a lower cut-off. 22 In our study, the incidence of VTE for patients with KS 2 was 5.1%, compared to 3.0% for patients with KS 0-1.
Other RAMs used to stratify patients admitted with acute medical illnesses include IMPROVE and the Padua Prediction Score. [18] [19] [20] 31 Although both these scores include an active diagnosis of cancer as an important contributing factor they have not been validated specifically to stratify risk in cancer inpatients.
Risk factors previously shown to be associated with higher VTE risk in cancer inpatients include African American ethnicity, older age, female gender, cancer site (including GI cancer, kidney, brain, ovary, and lung) the use of red cell or platelet transfusions and certain comorbidities. 32 Our analysis differs from these prior studies as both older age and female gender were shown to be associated with lower VTE risk. These differences may be related to the greater proportion of genitourinary cancers and hematologic malignancies in our study population as compared to prior studies.
Our study has certain limitations. Although a large number of patients were included in the final analysis, a significant number (n 5 439; 12%) had to be excluded as one or more data components to calculate the KS were missing. Moreover, due to the retrospective nature of the study, diagnostic studies were only performed when clinically indicated; prospective design with scheduled screening might lead to a more accurate estimation of VTE rate. Asymptomatic VTE on admission could not be excluded and as this was a retrospective study patient were not be objectively screened for VTE. Events such as ICU admission or surgery during the admission and total LOS almost certainly influence risk of VTE, but because they were not known on the day of admission, we chose not to include them in this analysis. Similarly we did not have any data on post discharge VTE events; rates could be potentially higher if this could be accounted for. Indeed in a large, multicenter prospective study of over 15 000 patients aiming to validate IMPROVE score, 45% of all VTE events occurred post discharge. 20 
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